BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
Mar 31, 2026 • 9min
CellCentric has kicked off dosing of its first registration-supporting study for the oral p300/CBP inhibitor inobrodib in multiple myeloma today
The first patient was dosed in DOMMINO-1, a Phase 2 open-label, single-arm study enrolling 100 adult patients across clinical sites in the UK and U.S.. It could potentially offer an accelerated approval opportunity if it reaches a high enough response rate.
Mar 25, 2026 • 22min
Solid Biosciences CEO Bo Cumo discusses recent DMD data for the company's microdystrophin gene therapy, and explains the development and regulatory steps ahead
He describes data presented at the Muscular Dystophy Association Annual Meeting which showed biopsy and safety data for 20 patients who have been followed for 90 days and 3 who are out to a year. Plus, explaining the three FDA meetings that are key ffor the company.
Mar 25, 2026 • 7min
Christian Tidona's BioMed X and Michal Preminger are launching BioMed X Venture Labs in Cambridge, MA to create 'build to solve' startups with partners
Michal Preminger will lead BioMed X Venture labs as CEO, and it will partner with pharma, foundations, and VCs to build mission driven companies.
Mar 23, 2026 • 10min
Apogee Therapeutics' CEO Michael Henderson discusses today's 52 week maintenance data for the company's extended-dose IL-13 inhibitor it atopic dermatitis
He discusses the the data and how he compares it to Dupixent and other medicines on the market, how translatable the data might be to a phase 3 that will be up and running later this year, and what other data the company will have in the near future.
Mar 20, 2026 • 40min
Biotech CEOs discuss the importance of culture, getting through challenging times, their policy wishlist, and how they are proud of the ways our industry gives back
MassBio President & CEO Kendalle Burlin O'Connell moderates a discussion with Zag Bio CEO Jason Cole and Altido Therapeutics CEO Chip Clark about running early stage companies and what advice they have for new CEOs. They offer advice about what it will take to keep our ecosystem globally competitive.
Mar 20, 2026 • 10min
From London: Yellowstone Biosciences is leveraging an Oxford AML patient biobank to develop an HLA Class II platform of T-cell engagers
From Syncona's Capital Markets Day, CEO Jim MacDonald describes the learnings Yellowstone has gained from looking at cured AML patients from the Oxford biobank and how it is translating that into new medicines.
Mar 20, 2026 • 11min
From London: Edward Hodgkin is the Executive Chair of Syncona's 'Slingshot', a platform that takes early stage science from academic labs that isn't ready to be a company and helps matures it
From Syncona's Capital Markets Day, he describes Slingshot and how he believes it differs from other early stage VC investors. Once an asset is ready for the clinic, Slingshot will either partner it or build its own company.
Mar 20, 2026 • 11min
From London: Purespring Therapeutics is developing a gene therapy that is delivered locally to the podocytes in the kidney and aims to treat IgAN as its initial indication
From Syncona's Capital Markets Day, CEO Haseeb Ahmed describes the science behind the platform, and make the case why IgAN, a condition that has seen a bevy of new therapies in development, is the right indication for a gene therapy.
Mar 19, 2026 • 15min
From London: Resolution Therapeutics is in the clinic with its engineered regenerative macrophage therapy to treat end stage liver disease
CEO Amir Hefni describes the ability of macrophages to reduce inflammation and reverse fibrosis in conditions like liver disease. An interim analysis for the clinical trial will read later this year.
Mar 19, 2026 • 12min
From London: With science from the Francis Crick Institute, ALTx Therapeutics launched with £12.55m last month to target cancers that rely on the Alternative Lengthening of Telomeres (ALT)
From Syncona's Capital Markets Day, ALTx founder and Francis Crick researcher Simon Boulton describes ALTs and the science behind how the company plans to target them.
